Anatomic localization of B cells within the spleen is associated with different functions in an immune response, but the biochemical pathways that control these differences are unknown. In mice transgenic for IgM carrying the VH81X variable region, B cells expressing an autoreactive idiotype are positively selected and persist in a particular anatomic location in the spleen, but antibody production by these cells is undetectable. In preliminary studies of the biochemical mechanisms of regulation of these autoreactive cells, evidence of increased signaling after antigen receptor (AgR) ligation was observed, in contrast to the suppressed signaling demonstrated in previous transgenic models of B cell clonal anergy. Further data suggest that the increased AgR signaling may be a general property of cells in the same region. this suggests a novel mechanism of regulation of certain auto-reactive B cells in the spleen, associated with increased AgR signaling but suppression of differentiation into antibody secreting cells, likely associated with specialized functions, perhaps related to immunologic memory. To begin to characterize regulatory mechanisms in such cells, this project will analyze 1) differences in AgR signaling in different splenic B cell subsets, 2) differences in AgR signaling between the transgenic auto-reactive cells and other B cells, and 3) the role of accessory membrane proteins in modulating AgR signaling in different subsets and in auto-reactive cells. Changes in intracellular calcium, by flow cytometry, and protein tyrosine phosphorylation, by immunoblotting of whole cell lysates, will be analyzed after AgR ligation in B cells separated into subsets on the basis of cell surface markers. The transgenic auto-reactive B cells will be selectively stimulated with anti-idiotypic or anti-allotypic antibodies and signaling compared to normal cells. Accessory membrane protein function will be compared between normal subsets and between normal cells and those expressing the auto-reactive idiotype. The intermediate goal is to identify cytoplasmic enzymatic pathways, by in vitro reactions, or nuclear transcription factors, using gel shift assays or polymerase chain reaction, that are differentially regulated in B cell subsets, particularly those where auto-reactive cells persist. The long term goal is to find how antibody secretion is regulated in clonally persistent auto-reactive B cells, and to identify potential targets for therapeutic intervention when this regulation fails.

Project Start
1998-01-01
Project End
1998-12-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
21
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Wu, Jianming; Xie, Fenglong; Qian, Kun et al. (2011) FAS mRNA editing in Human Systemic Lupus Erythematosus. Hum Mutat 32:1268-77
Wang, Feng; Ezell, Scharri J; Zhang, Yong et al. (2010) FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest New Drugs 28:234-41
Wang, Wei; Rayburn, Elizabeth R; Velu, Sadanandan E et al. (2009) In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res 15:3511-8
Wang, Wei; Rayburn, Elizabeth R; Zhao, Yuqing et al. (2009) Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett 278:241-248
Wang, Wei; Rayburn, Elizabeth R; Hang, Jie et al. (2009) Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer 65:306-11
Wang, Wei; Rayburn, Elizabeth R; Hao, Miao et al. (2008) Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 68:809-19
Annis, Douglas S; Gunderson, Kristin A; Mosher, Deane F (2007) Immunochemical analysis of the structure of the signature domains of thrombospondin-1 and thrombospondin-2 in low calcium concentrations. J Biol Chem 282:27067-75
Rayburn, Elizabeth R; Wang, Wei; Zhang, Ruiwen et al. (2007) Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol 30:1511-9
Annis, D S; Murphy-Ullrich, J E; Mosher, D F (2006) Function-blocking antithrombospondin-1 monoclonal antibodies. J Thromb Haemost 4:459-68
Rayburn, Elizabeth R; Wang, Wei; Zhang, Zhuo et al. (2006) Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. Prostate 66:1653-63

Showing the most recent 10 out of 145 publications